News
BMY
55.83
-1.73%
-0.98
10 levered big-caps that may face higher refinancing expenses
Seeking Alpha · 7h ago
Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
TipRanks · 1d ago
Labor Market Report Is Bad News On Rate Cuts, But Good News On Stock Market Performance
Seeking Alpha · 1d ago
10 Funds To Retire Today; $6,000 Monthly Income
Seeking Alpha · 1d ago
SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study
NASDAQ · 2d ago
Pharma companies welcome new year with 583 drug price hikes so far
Seeking Alpha · 3d ago
IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out
MarketWatch · 3d ago
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Benzinga · 3d ago
Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead
Barchart · 3d ago
Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap
Seeking Alpha · 3d ago
Novo, Eli Lilly to dominate global pharma sales in 2025: report
Seeking Alpha · 3d ago
J&J Pauses Sales of Atrial Fibrillation Device, Stock Down
NASDAQ · 3d ago
Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills
Seeking Alpha · 3d ago
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
NASDAQ · 3d ago
This Unpopular Dividend Stock Is a Buy
The Motley Fool · 3d ago
San Francisco Police Cancel Time Off as Healthcare Executives Descend
Barron‘s · 4d ago
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
Benzinga · 4d ago
IVE, BMY, SCHW, CB: Large Outflows Detected at ETF
NASDAQ · 4d ago
Latest Memo From Howard Marks: On Bubble Watch
Seeking Alpha · 4d ago
Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?
Barchart · 4d ago
More
Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.